SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 27, 2001
CERUS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-21937 68-0262011
(State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
2411 Stanwell Drive
Concord, California 94520
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (925) 288-6000
ITEM 5. OTHER EVENTS.
Cerus Corporation has development and commercialization agreements with
Baxter Healthcare Corporation for the joint development of the INTERCEPT
Platelet, Red Blood Cell and Plasma Systems. These agreements and their
applicable amendments have been filed with the SEC as exhibits to prior
filings. Cerus is filing certain of these agreements as exhibits to this
report in accordance with requests for continued confidential treatment of
certain terms.
ITEM 7. EXHIBITS
EXHIBIT
NUMBER DESCRIPTION OF EXHIBIT
------- ----------------------
10.17* Development, Manufacturing and Marketing Agreement, dated December 10,
1993, by and between Cerus and Baxter Healthcare Corporation.
10.18* Development, Manufacturing and Marketing Agreement, dated April 1, 1996,
by and between Cerus and Baxter Healthcare Corporation.
10.32* Second Amendment to Development, Manufacturing and Marketing Agreement,
dated June 30, 1998, by and between Cerus and Baxter Healthcare Corporation.
--------------------
* The Company has requested continued confidential treatment with respect
to certain portions of this exhibit.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CERUS CORPORATION
Dated: August 27, 2001 By: /s/ HOWARD G. ERVIN
---------------------------------------
Howard G. Ervin
Vice President, Legal Affairs
2
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION OF EXHIBIT
------- ----------------------
10.17* Development, Manufacturing and Marketing Agreement, dated December 10,
1993, by and between Cerus and Baxter Healthcare Corporation.
10.18* Development, Manufacturing and Marketing Agreement, dated April 1, 1996,
by and between Cerus and Baxter Healthcare Corporation.
10.32* Second Amendment to Development, Manufacturing and Marketing Agreement,
dated June 30, 1998, by and between Cerus and Baxter Healthcare Corporation.
--------------------
* The Company has requested continued confidential treatment with respect
to certain portions of this exhibit.